Aminaftone in the Treatment of Raynaud’s Phenomenon in Systemic Sclerosis: New Perspectives
American Journal of Internal Medicine
Volume 3, Issue 5, September 2015, Pages: 204-209
Received: Aug. 3, 2015; Accepted: Aug. 10, 2015; Published: Aug. 19, 2015
Views 3775      Downloads 70
Authors
Simone Parisi, Department of General and Specialist Medicine, Division of Rheumatology, University Hospital Città della Salute e della Scienza di Torino, Turin, Italy
Marco Scarati, Department of General and Specialist Medicine, Division of Rheumatology, University Hospital Città della Salute e della Scienza di Torino, Turin, Italy
Marta Priora, Department of General and Specialist Medicine, Division of Rheumatology, University Hospital Città della Salute e della Scienza di Torino, Turin, Italy
Clara Lisa Peroni, Department of General and Specialist Medicine, Division of Rheumatology, University Hospital Città della Salute e della Scienza di Torino, Turin, Italy
Angela Laganà, Department of General and Specialist Medicine, Division of Rheumatology, University Hospital Città della Salute e della Scienza di Torino, Turin, Italy
Enrico Fusaro, Department of General and Specialist Medicine, Division of Rheumatology, University Hospital Città della Salute e della Scienza di Torino, Turin, Italy
Article Tools
Follow on us
Abstract
Objective: The aim of this study was to assess the efficacy (in terms of improved VAS Pain, Raynaud's Phenomenon attacks frequency and Raynaud’s Condition Score) of the Aminaftone in patients with Raynaud’s Phenomenon (RP) secondary to Systemic Sclerosis (SSc). Methods: Open label controlled study. We evaluated the efficacy of Aminaftone in the treatment of secondary RP in 108 patients with SSc consecutively recruited and divided in two groups. Group A: 51 Patients in treatment with Calcium Channel Blockers, prostanoids (iloprost 2ng [min/kg every 4 weeks), Endothelin Receptor Antagonist and Phosphodiesterase-5 inhibitors (Standard of Care). Group B: 57 Patients in treatment with Calcium Channel Blockers, Prostanoids, Endothelin Receptor Antagonist and Phosphodiesterase-5 inhibitors and Aminaftone (Standard of care + Aminaftone). Results: The number of RP attacks in group treated with Aminaftone (Group B) was lower than the group treated with standard therapy (Group A) from baseline to Week 48, obtaining statistically significance (Δ A -1.50 Δ B -2.10 p=0.02 95%CI). The RCS was statistically significantly different (Δ A -1.60 Δ B -2.50 p=0,04 95% CI), as was the pain VAS(Δ A -20.80 Δ B -30.60 p=0.04 95%CI) at week 48. Conclusion: The use of Aminaftone was well tolerated and improved RP as measured by RCS and pain when added to standard of care. A well-designed randomized controlled trial is needed to determine if these preliminary findings are supported
Keywords
Raynaud’s Phenomenon, Systemic Sclerosis, Aminaftone, Endotheline
To cite this article
Simone Parisi, Marco Scarati, Marta Priora, Clara Lisa Peroni, Angela Laganà, Enrico Fusaro, Aminaftone in the Treatment of Raynaud’s Phenomenon in Systemic Sclerosis: New Perspectives, American Journal of Internal Medicine. Vol. 3, No. 5, 2015, pp. 204-209. doi: 10.11648/j.ajim.20150305.12
References
[1]
Kahaleh MB. Raynaud phenomenon and the vascular disease in scleroderma. Curr Opin Rheumatol 2004;16: 718–22.
[2]
Wigley FM. Clinical practice. Raynaud’s Phenomenon. N Engl J Med 2002;347:1001–8
[3]
Herrick AL. Pathogenesis of Raynaud’s phenomenon. Rheumatology 2005;44:587–96.
[4]
Blann A et al. Soluble markers of endothelial cell function. Clin Hemorhed Microcirc. 1997;17:3-11.
[5]
Rothlein R et al. A form of circulating ICAM-1 in human serum. J Immunol. 1991;147:3788-3793.
[6]
Mayes MD. Endothelin and endothelin receptor antagonists in systemic rheumatic disease. Arthritis Rheum 2003; 48:1190–9.
[7]
Black CM, Denton CP. The management of systemic sclerosis. Br J Rheumatol 1995;34:3 7.
[8]
Della Rossa A et al. Oral sildenafil in skin ulcers secondary to systemic sclerosis. Scand J Rheumatol. 2011;40(4):323-5. doi: 10.3109/03009742.2011.569755. Epub 2011 Jun 6. No abstract available.
[9]
Korn JH, Mayes M, Matucci Cerinic M et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004;50:3985–93.
[10]
Matucci-Cerinic M, Denton CP, Furst DE et al. Bosentan reduces the number of new digital ulcers in patients with systemic sclerosis (abstract). Ann Rheum Dis 2006;65: A3–49.
[11]
Parisi S et al. Efficacy of ambrisentan in the treatment of digital ulcers in patients with systemic sclerosis: a preliminary study. Rheumatology (Oxford). 2013 Jun;52(6):1142-4. doi: 10.1093/rheumatology/ket019. Epub 2013 Mar 5.
[12]
Villaverde CA et al. About vascular permeability with amonaftone. Revista de farmacologia Clinica y Experimental. 1989;6:9-14.
[13]
De Anna D et al. Effects of therapy with aminaftone on chronic venous and lymphatic stasis. Minerva Cardioangol. 1989;37:251-254.
[14]
Pereira de Godoy JM. Treatment of stasis dermatitis using aminaphtone: a case series. Journal of Medical Reports 2010,4:295.
[15]
Zambelli V et al. Efficacy of aminaftone in a rat model of monocrotaline-induced pulmonary hypertension. Eur J Pharmacol. 2011 Sep 30;667(1-3):287-91. doi: 10.1016/j.ejphar.2011.05.060. Epub 2011 May 30.
[16]
Scorza R et al. Aminaftone, a derivative of 4-aminobenzoic acid, downregulates endothelin-1 production in ECV304 Cells: an in vitro Study. Drugs R D. 2008;9(4):251-7.
[17]
Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581–90.
[18]
LeRoy EC et al. Scleroderma (Systemic Sclerosis): Classification, subsets and pathogenesis. J Rheumatol. 1988;15:202-205.
[19]
White et al. The American College of Rheumatolgy Committee on Design and Outcomes in Clinical Trials in Systemic Sclerosis. Guidelines for Clinical Trials in Systemic Sclerosis. I. Disease-modifying interventions. Arthritis Rheum. 1995;38:351-360.
[20]
Merkel PA, Herlyn K, Martin RW et al. Scleroderma Clinical Trials Consortium. Measuting disease activity and functional status patients with scleroderma and Raynaud’s phenomenon. Arthritis Rheum 2002;46:2410-20.
[21]
Garcıa de la Pena-Lefebvre P, Rodrı´guez Rubio S, Valero Exposito M et al. Long-term experience of bosentan for treating ulcers and healed ulcers in systemic sclerosis patients. Rheumatology 2008;47:464–6.
[22]
Selenko-Gebauer N, Duschek N, Minimair G, Stingl G, Karlhofer F. Successful treatment of patients with severe secondary Raynaud’s phenomenon with the endothelin receptor antagonist bosentan. Rheumatology 2006; 45(Suppl. 3):iii45–8.
[23]
Kamata Y, Minota S. Effects of phosphodiesterase type 5 inhibitors on Raynaud's phenomenon. Rheumatol Int. 2014 May 1. [Epub ahead of print].
[24]
Scorza R et al. Effects of aminaftone 75 mg TID on soluble adhesion molecules: a 12-week, randomized, open-label pilot study in patients with systemic sclerosis. Clin Ther. 2008 May;30(5):924-9. doi: 10.1016/j.clinthera.2008.05.009.
[25]
Ramos-Casals M, Brito-Zero´ n P, Nardi N et al. Successful treatment of severe Raynaud’s phenomenon with bosentan in four patients with systemic sclerosis. Rheumatology 2004;43:1454–6.
[26]
Yu EP, Ostor AJ, Hall FC. Successful treatment with bosentan for severe digital ischaemia in limited cutaneous systemic sclerosis. Ann Rheum Dis 2007;66: 1122–3.
[27]
Parisi S et al. Efficacy of bosentan in the treatment of Raynaud's phenomenon in patients with systemic sclerosis never treated with prostanoids. Reumatismo. 2014 Mar 17;65(6):286-91. doi: 10.4081/reumatismo.2013.691.
[28]
Launay D, Diot E, Pasquier E et al. [Bosentan for treatment of active digital ulcers in patients with systemic sclerosis]. Presse Med 2006;35:587–92.
[29]
Nguyen VA, Eisendle K, Gruber I, Hugl B, Reider D, Reider N. Effect of the dual endothelin receptor antagonist bosentan on Raynaud's phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study. Rheumatology (Oxford). 2010 Mar;49(3):583-7. Epub 2009 Dec 29.
[30]
Seibold JR, Matucci-Cerenic M, denton CP, Furst DE, Mayer MD, Kramer F et al. Bosentan reduces the number of new digital ulcers in patients with systemic sclerosis. Ann Rheum Dis. 2006;65:90.
[31]
Moore TL, Vail A, Herrick AL. Assessment of digital vascular structure and function in response to bosentan in patients with systemic sclerosis-related Raynaud’s phenomenon. Rheumatology 2007;46:363–4.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186